Clinical Trial Update: Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the safety and efficacy of IQP-LH-101 for postprandial heartburn has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• IQP-LH-101

Snippet

Sponsor: InQpharm Group | Conditions: Postprandial Heartburn | Phase 4 | Status: COMPLETED